ArticlePharmaceutical nanotechnology2025
The Incorporation of Clove Essential Oil into Nanostructured Lipid Carrier for Improvement of the Delivery and Antioxidant Effects on the Fibroblast Cells.
Article in Pharmaceutical nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Hydrogel-Nanolipid Formulations for the Complex Anti-Inflammatory and Antimicrobial Therapy of Periodontitis.Pharmaceutics · 2025Article
- The Potential Application of Nanocarriers in Delivering Topical Antioxidants.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Advances in plant essential oils and drug delivery systems for skincare.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClove (
objectiveWe aimed to develop a Nanostructured Lipid Carrier (NLC) to enhance the benefits of CO.
methodsUsing the emulsification sonication method, a liquid lipid component, surfactant concentration, and a co-surfactant were optimized to create CO-loaded NLC (CO-NLC). The developed CO-NLC was rigorously assessed for its stability during storage. Free radical scavenging activity and fibroblast oxidative stress protection were also measured to assess the antioxidant activity.
resultsThe CO-NLC displayed a spherical shape with a hydrodynamic diameter of 125.77 ± 29.68 nm, homogenous particle distribution with polydispersity index of 0.26 ± 0.09, and a surface charge of -27.30 ± 4.56 mV with an encapsulation efficiency of 97% and a good stability profile. Furthermore, free CO and CO-NLC displayed very strong free radical scavenging activity with the IC50 value of 22.74 ± 0.57 μg/mL and 18.28 ± 2.63 μg/mL, respectively. However, only CO-NLC managed to protect fibroblast cells from the harmful effects of oxidative stress.
conclusionThe NLC formulations improved free radical scavenging activity and effectively protected fibroblasts from oxidative stress compared to free CO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.